{"id":"sodium-stibogluconate-ssg","safety":{"commonSideEffects":[{"rate":null,"effect":"Arthralgia and myalgia"},{"rate":null,"effect":"Pancreatitis"},{"rate":null,"effect":"Cardiotoxicity (QT prolongation)"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Renal impairment"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL3764926","moleculeType":"Small molecule","molecularWeight":"909.89"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The drug is converted intracellularly to trivalent antimony, which disrupts the parasite's energy metabolism and generates oxidative stress leading to parasite death. It has been the first-line treatment for leishmaniasis for decades, though the exact molecular mechanism remains incompletely understood. The compound accumulates in infected macrophages where Leishmania resides.","oneSentence":"Sodium stibogluconate is a pentavalent antimony compound that kills Leishmania parasites by generating reactive oxygen species and inhibiting their glycolytic enzymes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:12.697Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Visceral leishmaniasis"},{"name":"Cutaneous leishmaniasis"},{"name":"Mucocutaneous leishmaniasis"}]},"trialDetails":[{"nctId":"NCT07496944","phase":"NA","title":"Effects of Blood Flow Restriction and Small-Sided Games on Soccer Passing and Dribbling Stability Under Fatigue","status":"COMPLETED","sponsor":"Beijing Sport University","startDate":"2026-01-20","conditions":"Athletic Performance","enrollment":40},{"nctId":"NCT07463040","phase":"PHASE3","title":"Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL)","status":"NOT_YET_RECRUITING","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2027-01-01","conditions":"Cutaneous Leihmaniasis","enrollment":900},{"nctId":"NCT05957978","phase":"PHASE2","title":"LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2024-03-29","conditions":"Primary Visceral Leishmaniasis","enrollment":52},{"nctId":"NCT06798402","phase":"PHASE2","title":"Ciprofloxacin Intralesional Injection for the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stibogluconate","status":"RECRUITING","sponsor":"Al-Mustafa University College","startDate":"2025-02-07","conditions":"Cutaneous Leishmaniasis","enrollment":80},{"nctId":"NCT04342715","phase":"","title":"A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of York","startDate":"2022-05-22","conditions":"Visceral Leishmaniasis","enrollment":216},{"nctId":"NCT04699383","phase":"","title":"Documentation of Patient Outcomes for SSG/Allopurinol Combination Treatment in Ethiopia","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2021-02-15","conditions":"Cutaneous Leishmaniasis","enrollment":105},{"nctId":"NCT03129646","phase":"PHASE3","title":"Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2018-01-24","conditions":"Visceral Leishmaniasis","enrollment":439},{"nctId":"NCT00508963","phase":"","title":"Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis","status":"NO_LONGER_AVAILABLE","sponsor":"University of California, San Francisco","startDate":"","conditions":"Leishmaniasis, Cutaneous, Leishmaniasis, Mucocutaneous","enrollment":""},{"nctId":"NCT05708625","phase":"PHASE3","title":"Intralesional Voriconazole, or Intralesional Cryotherapy, or Oral Doxycycline in the Treatment of Cutaneous Leishmaniasis","status":"UNKNOWN","sponsor":"Zagazig University","startDate":"2022-01-01","conditions":"Leishmaniasis, Cutaneous","enrollment":136},{"nctId":"NCT04906031","phase":"PHASE2","title":"Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Jinan University","startDate":"2020-06-01","conditions":"Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myeloid Malignancy","enrollment":5},{"nctId":"NCT04884074","phase":"NA","title":"Effect of Routine Anterior Crural Repair in De-Novo Gastroesophageal Reflux After Laparoscopic Sleeve Gastrectomy","status":"UNKNOWN","sponsor":"Chinese University of Hong Kong","startDate":"2021-05-01","conditions":"Obesity, Gastro Esophageal Reflux Disease","enrollment":50},{"nctId":"NCT00662012","phase":"PHASE2","title":"Sodium Stibogluconate Treatment of Leishmaniasis","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2002-06","conditions":"Leishmaniasis","enrollment":414},{"nctId":"NCT00498979","phase":"PHASE1","title":"Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2007-05","conditions":"Stage IV Melanoma","enrollment":22},{"nctId":"NCT00884377","phase":"PHASE2","title":"Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2004-02","conditions":"Cutaneous Leishmaniasis","enrollment":56},{"nctId":"NCT00657618","phase":"PHASE1, PHASE2","title":"Use of Sodium Stibogluconate as a Treatment for Leishmaniasis","status":"COMPLETED","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2004-10","conditions":"Leishmaniasis","enrollment":77},{"nctId":"NCT00629200","phase":"PHASE1","title":"Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-09-13","conditions":"Advanced Cancer, Solid Tumors","enrollment":33},{"nctId":"NCT00311558","phase":"PHASE1","title":"Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2005-10","conditions":"Cancer","enrollment":18},{"nctId":"NCT01067443","phase":"PHASE2","title":"Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2010-03","conditions":"Primary Visceral Leishmaniasis","enrollment":151},{"nctId":"NCT03009422","phase":"NA","title":"Fractional CO2 Laser With Topical Pentostam Treatment for Cutaneous Leishmaniasis.","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2014-11","conditions":"Leishmaniasis","enrollment":20},{"nctId":"NCT00255567","phase":"PHASE3","title":"Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2004-11","conditions":"Visceral Leishmaniasis","enrollment":1142},{"nctId":"NCT02281669","phase":"","title":"Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2014-11","conditions":"Cutaneous Leishmaniasis","enrollment":100},{"nctId":"NCT01011309","phase":"PHASE2","title":"A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis","status":"COMPLETED","sponsor":"Access to Advanced Health Institute (AAHI)","startDate":"2009-10","conditions":"Cutaneous Leishmaniasis","enrollment":45},{"nctId":"NCT01009502","phase":"PHASE1","title":"Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2009-07","conditions":"Myelodysplastic Syndromes","enrollment":1},{"nctId":"NCT01661296","phase":"PHASE4","title":"Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India","status":"COMPLETED","sponsor":"Sarder Patel Medical College","startDate":"2009-08","conditions":"Cutaneous Leishmaniasis","enrollment":100},{"nctId":"NCT00996463","phase":"PHASE2","title":"Rationales for Wound Care Management in Old World Cutaneous Leishmaniasis Patients","status":"COMPLETED","sponsor":"Waisenmedizin e. V. Promoting Access to Essential Medicine","startDate":"2010-01","conditions":"Wound Healing","enrollment":63}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":139,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pentostam (GlaxoSmithKline)"],"phase":"phase_3","status":"active","brandName":"Sodium Stibogluconate (SSG)","genericName":"Sodium Stibogluconate (SSG)","companyName":"U.S. Army Medical Research and Development Command","companyId":"u-s-army-medical-research-and-development-command","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sodium Stibogluconate (SSG) is a small molecule used to treat various conditions, including Cutaneous Leishmaniasis, Primary Visceral Leishmaniasis, and Myelodysplastic Syndromes. It is also being studied in clinical trials for its potential use in treating Cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}